Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Research & Development (2016 - 2025)

Historic Research & Development for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $177.2 million.

  • Arrowhead Pharmaceuticals' Research & Development rose 2934.34% to $177.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $647.4 million, marking a year-over-year increase of 2298.32%. This contributed to the annual value of $607.2 million for FY2025, which is 2002.27% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Research & Development is $177.2 million, which was up 2934.34% from $174.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Research & Development's 5-year high stood at $177.2 million during Q4 2025, with a 5-year trough of $44.7 million in Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $97.3 million (2023), whereas its average is $105.5 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Research & Development surged by 8212.94% in 2021, and later plummeted by 145.29% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Research & Development (Quarter) stood at $65.8 million in 2021, then rose by 27.26% to $83.7 million in 2022, then skyrocketed by 39.19% to $116.5 million in 2023, then increased by 17.61% to $137.0 million in 2024, then grew by 29.34% to $177.2 million in 2025.
  • Its Research & Development stands at $177.2 million for Q4 2025, versus $174.7 million for Q3 2025 and $162.4 million for Q2 2025.